PRNewswire - February 6, 2003

Ingelheim, Germany - Clinical trial program is largest ever for HIV-positive patients previously treated with three classes of antiretrovirals

Boehringer Ingelheim today announced the launch of the Phase III RESIST clinical trial program designed to further study the efficacy and safety of tipranavir for use in combination therapy for HIV-1 infection. The RESIST 1 & 2 trials and accompanying companion studies will evaluate triple class-experienced patients(1) in more than 280 clinical trial sites worldwide. Tipranavir is the first non-peptidic protease inhibitor (NPPI) in development for the treatment of HIV-1 infection. It will be Boehringer Ingelheim's second antiretroviral drug following Viramune(R) (nevirapine), which is a non-nucleoside reverse transcriptase inhibitor.

Resistance to currently available anti-HIV drugs is an increasingly prevalent concern for highly treatment-experienced HIV-positive patients worldwide, creating an urgent need for new treatments that are effective against multi-drug resistant virus. Up to 14 percent of recently infected patients have been reported to be infected with a strain of virus that has drug resistance mutations or that has reduced susceptibility to a particular drug (resulting in reduced drug effectiveness) (2), (3), (4). Based on available clinical and in vitro data, tipranavir shows activity against multi-drug resistant HIV virus, offering hope for patients with multi-drug resistant virus.

"This is an important milestone in the development of tipranavir," said Dr. Andreas Barner, Member of the Board of Managing Directors of Boehringer Ingelheim. "We have designed a clinically relevant Phase III trial program that includes resistance testing for all patients, allows the use of other expanded access HIV/AIDS therapies, and provides access to a significant number of triple class-experienced patients worldwide. It's the largest trial program ever conducted in this patient population, recruiting over 1,500 patients in total."

The Phase III RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) clinical trial program has been designed to study the safety and efficacy of tipranavir (boosted with low-dose ritonavir) versus a low-dose ritonavir-boosted comparator protease inhibitor (PI) that is chosen by the patient's physician on the basis of treatment history and baseline resistance testing. Study participants will all be highly treatment-experienced HIV-positive adults. Phase III of clinical development is the final stage of testing before a drug is submitted to worldwide regulatory authorities for review and consideration for marketing approval. The RESIST Program consists of two Phase III pivotal trials (RESIST 1 and RESIST 2) and two companion trials (study 1182.51 and RESIST 3) available at some sites for even more advanced patients.

"Initial studies have demonstrated that tipranavir is among the most promising anti-HIV drugs in development -- particularly for treatment-experienced patients unable to construct a viable regimen with currently available antiretrovirals. I look forward to seeing the outcome of these important Phase III trials," said Kathleen Squires, MD, Associate Professor of Medicine of the Keck School of Medicine of the University of Southern California, and an investigator in the RESIST program.

RESIST Clinical Trial Program Design

RESIST 1 will enroll more than 500 patients in the USA, Canada and Australia. RESIST 2 will enroll more than 800 patients in Europe and in South America. The clinical endpoint for the RESIST 1 study is at 24 weeks and for the RESIST 2 study the endpoints are at 16 and 24 weeks. All participants will receive resistance testing at baseline to determine the optimal drugs to combine with tipranavir, as each patient will receive an individualized background treatment regimen. The choice of comparator PI and background regimen is up to the investigator.

Highly treatment experienced HIV-positive patients interested in enrolling in one of the RESIST trials should contact their local HIV/AIDS healthcare provider to find a local site that is participating in the trial.

Additional companion studies will also be available at some participating pivotal study sites for patients who do not qualify for the pivotal trial protocol. Boehringer Ingelheim will also study tipranavir in treatment-naive adult patients and conduct trials in children. The dose for tipranavir that will be studied in the Phase III clinical program is 500 mg of tipranavir taken with 200 mg of ritonavir (to boost tipranavir drug levels in the body) twice daily.

Tipranavir

Tipranavir has a non-peptidic chemical structure, which allows it to bind more flexibly to the active site of the HIV protease. This flexibility appears to explain why the resistance profile of tipranavir is different from available peptidic PIs. While the exact resistance profile of tipranavir is still being defined, initial clinical and in vitro data indicate it is superior to currently available protease inhibitors. Results from Phase II clinical studies have shown that reduction in the susceptibility of HIV to tipranavir was very infrequent and was associated with at least 16 protease inhibitor mutations at baseline.

The HIV-1 virus acquires HIV drug resistance after sub-optimal exposure to antiretroviral therapy, which becomes more of an issue the longer patients are receiving treatment. Drug resistance may render drugs less effective, or even ineffective, thus significantly limiting treatment options for people with HIV/AIDS. Resistance generally occurs as a result of changes -- or mutations -- in HIV's genetic code.

Boehringer Ingelheim

Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. Viramune(R) (nevirapine) is a product of original research done at Boehringer Ingelheim Pharmaceuticals, Inc, a member of the Boehringer Ingelheim group of companies. Viramune(R) was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs. Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor tipranavir. The company is involved in basic research and is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals. For more information on Boehringer Ingelheim, please visit http://www.boehringer-ingelheim.com/hiv .

The Boehringer Ingelheim group of companies, headquartered in Ingelheim, Germany, is one of the 20 leading pharmaceutical corporations in the world. In 2001, it posted revenues of EUR 6.7 billion.

Boehringer Ingelheim, which has some 140 affiliated companies in 42 countries worldwide, focuses on human pharmaceuticals and animal health. The human pharmaceuticals business, which accounts for 95% of sales, is comprised of prescription medicines, consumer health care products, chemicals and biopharmaceuticals for industrial customers. Research and development, production, and distribution facilities are located around the globe. In 2001, Boehringer Ingelheim's R&D spending was more than EUR 1 billion which is almost a fifth of net sales in Prescription Medicines.

For more information on Boehringer Ingelheim, please visit the international Internet website http://www.boehringer-ingelheim.com/ .

References:

(1) Previously treated with three classes of antiretrovirals: nucleoside analogues, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

(2) Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999 Sep 22-29;282(12):1135-41.

(3) Little SJ, Daar ES, D'Aquila RRT, Keiser PII, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999 Sep 22-29;282(12):1142-9.

(4) Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999 Aug 28;354(9180):729-33.

Source: Boehringer Ingelheim

Julia C. Kleinmann, Corporate Communications Division, Boehringer Ingelheim International GmbH, +49-6132-77-8271, Fax - +49-6132-77-6601,

kleinmann@ing.boehringer-ingelheim.com; or Noelle Boyd, GCI Healthcare, +1-512-689-2512, Fax - +1-212-537-8250,

for Boehringer Ingelheim Web site: http://www.boehringer-ingelheim.com/hiv http://www.boehringer-ingelheim.com/

030206
PR03027

Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019  http://www.PRNewswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .